Foresite Capital Management V’s CG Oncology CGON Stock Holding History

Foresite Capital Management V’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$76.7M	Buy	1,079,050 +75,000	+7%	+$4.9M	21.17%	2
2026 Q1	$68M	Hold	1,004,050	–	–	25.08%	2
2025 Q4	$41.7M	Hold	1,004,050	–	–	25.36%	2
2025 Q3	$40.4M	Hold	1,004,050	–	–	37.19%	1
2025 Q2	$26.1M	Buy	1,004,050 +145,000	+17%	+$3.49M	32.34%	1
2025 Q1	$21M	Buy	859,050 +166,500	+24%	+$4.68M	24.01%	2
2024 Q4	$19.9M	Hold	692,550	–	–	16.53%	3
2024 Q3	$26.1M	Hold	692,550	–	–	18.16%	3
2024 Q2	$21.9M	Hold	692,550	–	–	13.96%	3
2024 Q1	$30.4M	Buy	+692,550	New	+$28.3M	28.54%	2

Other funds holding CGON

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Foresite Capital Management V's CGON Position: Q2 2026 in Review

Foresite Capital Management V increased its CG Oncology (CGON) stake by 7.5% in Q2 2026, buying an estimated $4.9M and bringing the position to 1,079,050 shares worth $76.7M. The position accounts for 21.17% of the portfolio, ranked #2.

Foresite Capital Management V first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

Foresite Capital Management V held 1,079,050 shares of CG Oncology worth $76.7M as of Q2 2026.
Foresite Capital Management V bought 75,000 CG Oncology shares in Q2 2026, an estimated $4.9M.
CG Oncology made up 21.17% of Foresite Capital Management V's portfolio in Q2 2026, its #2 holding.
Foresite Capital Management V first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Foresite Capital Management V's 13F filing for Q2 2026, filed 14 Aug 2026.